Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory C Hadlock

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
AIDS Care|January 3, 2020
Risk factors for potentially preventable hospital readmissions among persons living with human immunodeficiency virus infectionGregory C Hadlock, Kelli Ann Moleres, Larry J Pineda, et al.
Journal of Neuroscience Methods|February 5, 2011
Ex vivo identification of protein-protein interactions involving the dopamine transporterGregory C Hadlock, Chad C Nelson, Anthony J Baucum, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 13, 2010
Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activationGregory C Hadlock, Pei-Wen Chu, Elliot T Walters, et al.
Journal of Neurochemistry|July 24, 2010
Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine releasePei-Wen Chu, Gregory C Hadlock, Paula Vieira-Brock, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2009
Mechanisms underlying methamphetamine-induced dopamine transporter complex formationGregory C Hadlock, Anthony J Baucum, Jill L King, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 4, 2011
4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuseGregory C Hadlock, Katy M Webb, Lisa M McFadden, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
AIDS Care|January 3, 2020
Risk factors for potentially preventable hospital readmissions among persons living with human immunodeficiency virus infectionGregory C Hadlock, Kelli Ann Moleres, Larry J Pineda, et al.
Journal of Neuroscience Methods|February 5, 2011
Ex vivo identification of protein-protein interactions involving the dopamine transporterGregory C Hadlock, Chad C Nelson, Anthony J Baucum, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 13, 2010
Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activationGregory C Hadlock, Pei-Wen Chu, Elliot T Walters, et al.
Journal of Neurochemistry|July 24, 2010
Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine releasePei-Wen Chu, Gregory C Hadlock, Paula Vieira-Brock, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2009
Mechanisms underlying methamphetamine-induced dopamine transporter complex formationGregory C Hadlock, Anthony J Baucum, Jill L King, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 4, 2011
4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuseGregory C Hadlock, Katy M Webb, Lisa M McFadden, et al.
Pageof 1